News | February 22, 2007

Now in Trial, Catheter-Based Device May Reduce Number of Surgeries for Congenital Heart Patients

Feb. 23, 2007 — The first patient implant was performed this week in a feasibility study evaluating the use Medtronic’s Melody Transcatheter Pulmonary Valve and Ensemble Transcatheter Delivery System to treat patients requiring congenital pulmonary heart valve replacement.

The prospective, non-randomized, feasibility clinical trial will enroll 30 patients at three U.S. medical centers including:

• Children's Hospital Boston (Boston, MA) with investigators James Lock, M.D. Cardiologist-in-Chief and Emile Bacha, M.D. Senior Associate in Cardiac Surgery

• Morgan Stanley Children's Hospital of New York - Presbyterian (New York, NY) with investigators Dr. William Hellenbrand, M.D. Director of Catheterization Laboratory for Congenital Heart Disease and Ralph Mosca, M.D. Director of Pediatric Cardiac Surgery

• Miami Children's Hospital (Miami, FL) with investigators Evan Zahn, M.D. Chief, Cardiology and Redmond Burke, M.D. Chief Cardiovascular Surgery

"We are excited about the promise of bringing this new, non-surgical procedure to the thousands of U.S. patients suffering from congenital heart disease with defects that disrupt the blood flow from the right ventricle to the pulmonary artery," said Dr. James Lock, Cardiologist-in-Chief at Children's Hospital Boston. "Our first implant has been conducted with positive results — both clinically and from a quality of life perspective — for the patient by delaying the need for an invasive open heart procedure to restore valve function."

"Effective management of congenital heart defects over a patient's lifetime requires dedicated collaboration between cardiac surgeons and interventional cardiologists," added Dr. John Mayer, Senior Associate in Cardiac Surgery at Children's Hospital Boston. "Together, members of these two disciplines draw on a variety of treatment options and clinical pathways. We hope that the Melody valve will be an important addition to the choices available for our patients."

The defect often requires open heart surgery early in life to implant a prosthetic or bioprosthetic valved-conduit to establish adequate blood flow from the heart to the lungs. However, the functional life span of these conduits is relatively limited, and as a result, most patients with this type of defect may require multiple open heart surgeries to place new valved conduits as they grow over their lifetime.

To meet this clinical need, Medtronic says it will use this trial to evaluate the Melody valve and Ensemble delivery system as a catheter-based alternative treatment in order to restore effective pulmonary valve function and potentially prolong the functional life of the right ventricle to pulmonary artery conduits. This alternative treatment is aimed at reducing the number of open heart surgeries these patients must undergo.

To date, more than 200 patients have been treated with the therapy. The Melody valve and Ensemble system are not currently available in the U.S., but Medtronic has received Canadian approval and CE Mark approval in Europe for commercial sale of the Medtronic Melody Transcatheter Pulmonary Valve and Ensemble Transcatheter Delivery System.

For more information visit www.medtronic.com.

Related Content

Thubrikar Announces First-in-Human Implant of Optimum TAVI System
News | Heart Valve Technology | January 29, 2019
Thubrikar Aortic Valve Inc. announced the first human implant of the Optimum TAV using their transcatheter aortic valve...
Perceval Valve Offers Performance, Economic Advantages in Aortic Disease Treatment
News | Heart Valve Technology | January 29, 2019
LivaNova PLC announced the publication of three separate studies highlighting the performance of its sutureless aortic...
First Tendyne Transcatheter Mitral Valve Implanted in New York
News | Heart Valve Technology | January 28, 2019
Lenox Hill Hospital is the first hospital in New York City to successfully implant Abbott’s Tendyne transcatheter...
Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Overlay Init